

Ioannis K Zervantonakis

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8323724/publications.pdf>

Version: 2024-02-01

60
papers

4,550
citations

172457

29
h-index

233421

45
g-index

65
all docs

65
docs citations

65
times ranked

7326
citing authors

#	ARTICLE	IF	CITATIONS
1	Mechanical Stress Signaling in Pancreatic Cancer Cells Triggers p38 MAPK- and JNK-Dependent Cytoskeleton Remodeling and Promotes Cell Migration via Rac1/cdc42/Myosin II. <i>Molecular Cancer Research</i> , 2022, 20, 485-497.	3.4	33
2	Therapy resistance: opportunities created by adaptive responses to targeted therapies in cancer. <i>Nature Reviews Cancer</i> , 2022, 22, 323-339.	28.4	107
3	Investigating key cell types and molecules dynamics in PyMT mice model of breast cancer through a mathematical model. <i>PLoS Computational Biology</i> , 2022, 18, e1009953.	3.2	5
4	A PDE Model of Breast Tumor Progression in MMTV-PyMT Mice. <i>Journal of Personalized Medicine</i> , 2022, 12, 807.	2.5	7
5	A SNAI2-PEAK1-INHBA stromal axis drives progression and lapatinib resistance in HER2-positive breast cancer by supporting subpopulations of tumor cells positive for antiapoptotic and stress signaling markers. <i>Oncogene</i> , 2021, 40, 5224-5235.	5.9	11
6	A Mathematical Model of Breast Tumor Progression Based on Immune Infiltration. <i>Journal of Personalized Medicine</i> , 2021, 11, 1031.	2.5	18
7	A large peptidome dataset improves HLA class I epitope prediction across most of the human population. <i>Nature Biotechnology</i> , 2020, 38, 199-209.	17.5	324
8	Perturbation biology links temporal protein changes to drug responses in a melanoma cell line. <i>PLoS Computational Biology</i> , 2020, 16, e1007909.	3.2	15
9	Large-Scale Characterization of Drug Responses of Clinically Relevant Proteins in Cancer Cell Lines. <i>Cancer Cell</i> , 2020, 38, 829-843.e4.	16.8	40
10	Fibroblast-tumor cell signaling limits HER2 kinase therapy response via activation of MTOR and antiapoptotic pathways. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 16500-16508.	7.1	23
11	Tuning Nanoparticle Interactions with Ovarian Cancer through Layer-by-Layer Modification of Surface Chemistry. <i>ACS Nano</i> , 2020, 14, 2224-2237.	14.6	64
12	Improving cancer combination therapy by timing drug administration. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	1
13	Not all fibroblasts are equal in cancer. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	1
14	Cancer-immune topology influences lung cancer evolution. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	0
15	Uncovering metabolic states in cytotoxic T cells, one cell at a time. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	0
16	Modeling the impact of genetic heterogeneity on immunotherapy. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	0
17	Perturbation biology links temporal protein changes to drug responses in a melanoma cell line. , 2020, 16, e1007909.		0
18	Perturbation biology links temporal protein changes to drug responses in a melanoma cell line. , 2020, 16, e1007909.		0

#	ARTICLE	IF	CITATIONS
19	Perturbation biology links temporal protein changes to drug responses in a melanoma cell line. , 2020, 16, e1007909.		0
20	Perturbation biology links temporal protein changes to drug responses in a melanoma cell line. , 2020, 16, e1007909.		0
21	Pooled Genomic Screens Identify Anti-apoptotic Genes as Targetable Mediators of Chemotherapy Resistance in Ovarian Cancer. Molecular Cancer Research, 2019, 17, 2281-2293.	3.4	29
22	Combined MEK and BCL-2/XL Inhibition Is Effective in High-Grade Serous Ovarian Cancer Patient-Derived Xenograft Models and BIM Levels Are Predictive of Responsiveness. Molecular Cancer Therapeutics, 2019, 18, 642-655.	4.1	39
23	BRAF and AXL oncogenes drive RIPK3 expression loss in cancer. PLoS Biology, 2018, 16, e2005756.	5.6	56
24	Endothelial monolayer permeability under controlled oxygen tension. Integrative Biology (United Tj ETQq0 0 0 rgBTJ /Overlock_10 Tf 50	1.3	37
25	Establishment of Patient-Derived Tumor Xenograft Models of Epithelial Ovarian Cancer for Preclinical Evaluation of Novel Therapeutics. Clinical Cancer Research, 2017, 23, 1263-1273.	7.0	95
26	Systems analysis of apoptotic priming in ovarian cancer identifies vulnerabilities and predictors of drug response. Nature Communications, 2017, 8, 365.	12.8	44
27	Abstract PR01: Systems analysis of signaling pathway adaptation to design effective PI3K-based combination therapies using ovarian cancer patient-derived xenografts. , 2017, , .		0
28	Abstract 4033: Combined MEK and BCL-2/XLinhibition as a potential drug combination for the treatment of high-grade serous ovarian cancer. , 2017, , .		0
29	Controlled Drug Release and Chemotherapy Response in a Novel Acoustofluidic 3D Tumor Platform. Small, 2016, 12, 2616-2626.	10.0	33
30	A protein interaction map for cell-cell adhesion regulators identifies DUSP23 as a novel phosphatase for β -catenin. Scientific Reports, 2016, 6, 27114.	3.3	13
31	Neutrophils Suppress Intraluminal NK Cell-Mediated Tumor Cell Clearance and Enhance Extravasation of Disseminated Carcinoma Cells. Cancer Discovery, 2016, 6, 630-649.	9.4	369
32	Growth inhibition in a brain metastasis model by antibody delivery using focused ultrasound-mediated blood-brain barrier disruption. Journal of Controlled Release, 2016, 238, 281-288.	9.9	86
33	Mutant p53 regulates ovarian cancer transformed phenotypes through autocrine matrix deposition. JCI Insight, 2016, 1, .	5.0	45
34	Abstract PR12: Mutant p53 drives early events in fallopian tube tumorigenesis through mesenchyme-associated autocrine production of matrix that supports survival and mesothelial intercalation.. , 2016, , .		0
35	Abstract B48: Design of effective combination therapies for high-grade serous ovarian cancer using patient-derived xenograft models.. , 2016, , .		0
36	Abstract 3843: Design of effective combination therapies for high-grade serous ovarian cancer using patient-derived xenograft models. , 2016, , .		0

#	ARTICLE	IF	CITATIONS
37	Controlled electromechanical cell stimulation on-a-chip. Scientific Reports, 2015, 5, 11800.	3.3	97
38	Registered report: Discovery and preclinical validation of drug indications using compendia of public gene expression data. ELife, 2015, 4, e06847.	6.0	3
39	Abstract PR01: Adaptive resistance of patient-derived ovarian cancer cells to PI3K/mTOR inhibition. , 2015, , .		0
40	Synergistic Effects of 3D ECM and Chemogradients on Neurite Outgrowth and Guidance: A Simple Modeling and Microfluidic Framework. PLoS ONE, 2014, 9, e99640.	2.5	17
41	Theoretical and Experimental Framework of Neurite Response to Chemical Gradients in 3D Matrices. Biophysical Journal, 2014, 106, 572a.	0.5	0
42	Screening therapeutic EMT blocking agents in a three-dimensional microenvironment. Integrative Biology (United Kingdom), 2013, 5, 381-389.	1.3	150
43	Tumor cell migration in complex microenvironments. Cellular and Molecular Life Sciences, 2013, 70, 1335-1356.	5.4	183
44	In Vitro Model of Tumor Cell Extravasation. PLoS ONE, 2013, 8, e56910.	2.5	201
45	Abstract A7: Targeting mutant p53 and cell-cell adhesion in ovarian cancer. , 2013, , .		0
46	Three-dimensional microfluidic model for tumor cell intravasation and endothelial barrier function. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 13515-13520.	7.1	744
47	A novel microfluidic platform for high-resolution imaging of a three-dimensional cell culture under a controlled hypoxic environment. Lab on A Chip, 2012, 12, 4855.	6.0	134
48	Microfluidic assay for simultaneous culture of multiple cell types on surfaces or within hydrogels. Nature Protocols, 2012, 7, 1247-1259.	12.0	518
49	Ensemble Analysis of Angiogenic Growth in Three-Dimensional Microfluidic Cell Cultures. PLoS ONE, 2012, 7, e37333.	2.5	102
50	Engineering of In Vitro 3D Capillary Beds by Self-Directed Angiogenic Sprouting. PLoS ONE, 2012, 7, e50582.	2.5	78
51	A high-throughput microfluidic assay to study neurite response to growth factor gradients. Lab on A Chip, 2011, 11, 497-507.	6.0	145
52	Spectrally resolved multidepth fluorescence imaging. Journal of Biomedical Optics, 2011, 16, 096015.	2.6	17
53	Spectrum resolved fluorescence imaging in multi-focal volume holographic microscopy. , 2011, , .		0
54	Microfluidic devices for studying heterotypic cell-cell interactions and tissue specimen cultures under controlled microenvironments. Biomicrofluidics, 2011, 5, 013406.	2.4	117

#	ARTICLE	IF	CITATIONS
55	Concentration gradients in microfluidic 3D matrix cell culture systems. International Journal of Micro-nano Scale Transport, 2010, 1, 27-36.	0.2	30
56	Microfluidic Platforms for Studies of Angiogenesis, Cell Migration, and Cell-Cell Interactions. Annals of Biomedical Engineering, 2010, 38, 1164-1177.	2.5	140
57	Transport-mediated angiogenesis in 3D epithelial coculture. FASEB Journal, 2009, 23, 2155-2164.	0.5	179
58	Surface-Treatment-Induced Three-Dimensional Capillary Morphogenesis in a Microfluidic Platform. Advanced Materials, 2009, 21, 4863-4867.	21.0	85
59	A microfluidic platform for studying the effects of small temperature gradients in an incubator environment. Biomicrofluidics, 2008, 2, 34106.	2.4	24
60	A novel, view-independent method for strain mapping in myocardial elastography: eliminating angle and centroid dependence. Physics in Medicine and Biology, 2007, 52, 4063-4080.	3.0	61